(Q42474720)

1 November 2017

title

Inhibition of human cardiac fibroblast mitogenesis by blockade of mitogen-activated protein kinase and phosphatidylinositol 3-kinase (English)

1 reference

1 November 2017

S Hafizi

1

1 reference

1 November 2017

A H Chester

series ordinal

2

1 reference

1 November 2017

M H Yacoub

series ordinal

3

1 reference

1 November 2017

publication date

1 July 1999

1 reference

Clinical and Experimental Pharmacology and Physiology

1 November 2017

published in

1 reference

1 November 2017

volume

26

1 reference

1 November 2017

issue

7

1 reference

1 November 2017

page(s)

511-513

1 reference

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

Phosphoinositide 3-kinases: a conserved family of signal transducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

Binding to the platelet-derived growth factor receptor transiently activates the p85alpha-p110alpha phosphoinositide 3-kinase complex in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

Expression of functional angiotensin-converting enzyme and AT1 receptors in cultured human cardiac fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1 beta in pigs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

Cytoskeleton-disrupting drugs enhance effect of growth factors and hormones on initiation of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03071.X

10.1046/J.1440-1681.1999.03071.X

21 January 2018

Identifiers

DOI

1 reference

1 November 2017

1 reference